NCT06551909Recruiting
Radioimmunotherapy in Solid Tumors (PNRR-MCNT2-2023-12378239-Aim2)
Radioimmunotherapy in Solid Tumors (Aim 2- Stereotactic Neoadjuvant Radiotherapy for Glioblastoma)
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
This is a prospective multicenter study of hypofractionated radiotherapy for the radiation treatment (RT) of solid tumors and in particular for Glioblastoma (in Aim 2). It is based on the results of ongoing studies at our Institute to validate the efficacy of extremely hypofractionated RT in neoadjuvant settings, which observed immunostimulatory effects of RT and the synergy with immune components. The collaboration between San Raffaele Hospital (Milan), the IRCCS Istituto Nazionale dei Tumori Fondazione G. Pascale (Naples) and the San Giuseppe Moscati Hospital of National Relief and High Specialty (Avellino) will ensure that patient recruitment, treatment and monitoring can be translated into facilities of the National Health System using common procedures. The various departments involved will treat patients with the same methods synergistically exploring the immuno/biological factors related to efficacy (and/or toxicity), based on new radioimmunotherapeutic approaches. Clinical and research activity will be developed jointly, drawing on the expertise in radiotherapy, radiomics, oncology, imaging and immunotherapy skills already available.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 12 Aug 2024
- Start date
- 31 Aug 2024
- Primary completion date
- 28 Feb 2027
- Lead sponsor
- IRCCS San Raffaele
- Diseases
- Glioblastoma
- NCT number
- NCT06551909
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 31 Aug 2024 to the primary completion date, 28 Feb 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous stroke
Other
- Presence of another primary and/or metastatic tumor For healthy volunteers also, absence of primary and/or metastatic tumor
Who the study is looking for
- Diagnosis of Glioblastoma.
- ECOG performance score 0-2 (defined during the first visit)
- Surgically removable lesion (according to the operability criteria established by the Neurosurgery Unit)
- For healthy volunteers, people who are as comparable as possible with the patient population in terms of sex and age will be recruited
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS San Raffaele Scientific Institute Coordinator of this site? Confirm its status | Milan | Italy | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.